IN8bio (INAB)
(Delayed Data from NSDQ)
$1.00 USD
+0.02 (2.01%)
Updated Apr 17, 2024 03:59 PM ET
After-Market: $1.05 +0.05 (5.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for IN8bio, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 30 | 29 | 15 | 9 | 5 |
Income After Depreciation & Amortization | -30 | -29 | -15 | -9 | -5 |
Non-Operating Income | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -30 | -29 | -15 | -9 | -5 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -30 | -29 | -15 | -9 | -5 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -30 | -29 | -15 | -9 | -5 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -28 | -27 | -14 | -8 | -5 |
Depreciation & Amortization (Cash Flow) | 3 | 1 | 1 | 0 | 0 |
Income After Depreciation & Amortization | -30 | -29 | -15 | -9 | -5 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 29.87 | 20.97 | 9.97 | NA | NA |
Diluted EPS Before Non-Recurring Items | -1.00 | -1.36 | -1.47 | NA | NA |
Diluted Net EPS (GAAP) | -1.00 | -1.36 | -1.47 | -3.02 | NA |
Fiscal Year end for IN8bio, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 7.60 | 7.17 | 7.71 | 7.53 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -7.60 | -7.17 | -7.71 | -7.53 |
Non-Operating Income | NA | 0.33 | 0.00 | 0.00 | 0.00 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -7.60 | -7.17 | -7.72 | -7.53 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -7.60 | -7.17 | -7.72 | -7.53 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -7.60 | -7.17 | -7.72 | -7.53 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 35.80 | 31.55 | 28.47 | 24.73 |
Diluted EPS Before Non-Recurring Items | NA | -0.21 | -0.23 | -0.27 | -0.30 |
Diluted Net EPS (GAAP) | NA | -0.20 | -0.23 | -0.27 | -0.30 |